



ADULT Medication Monograph

HALOPERIDOL




This document should be read in conjunction with this [DISCLAIMER](#)

[Formulary: Restricted](#)

Class	Antipsychotic agent
Presentation	Tablet: 500microg, 5mg Ampoule: 5mg/mL Long Acting Injection: 50mg/mL as haloperidol decanoate
Storage	Store at room temperature, below 25°C. Protect from light.
Dose	<u>Control of Nausea and Vomiting (Palliative Care):</u> Oral: 0.5 - 1mg BD or at night <u>Nausea and Vomiting caused by Bowel Obstruction (Palliative Care):</u> Continuous subcutaneous infusion: 1 - 2.5mg / 24 hours Subcutaneous Injection: 0.5 – 1mg BD, and 0.5 – 1mg 4-hourly as required. Maximum of 5mg daily. <u>Acute Health Related Behavioural Disturbance/ Psychoses:</u> <i>*Not considered first-line - caution is advised*</i> Intramuscular injection: 5 – 10mg every 30 to 60 minutes, up to 20mg/24hrs (monitor with ECG where possible) Oral: 1 – 5mg every 30 minutes - 2 hours as needed. Maximum 20mg in 24 hours.

	<p>*For elderly: use low doses (0.5–10 mg daily) to avoid severe EPSE</p> <p><u>Chronic Psychoses</u></p> <p>Long acting injection, IM: 50 - 300mg every 4 weeks.</p>
Administration	Refer to the Australian Injectable Drugs Handbook
Pregnancy	<p>1st Trimester: Monitoring required</p> <p>2nd Trimester: Monitoring required</p> <p>3rd Trimester: Monitoring required</p> <p>For more information, please contact KEMH Obstetric Medicines Information Service.</p>
Breastfeeding	<p>Monitoring required</p> <p>For more information, please contact KEMH Obstetric Medicines Information Service.</p>
Monitoring	<p>Monitor vital signs when given by IM or IV injection. Resuscitation facilities must be readily available.</p> <p>Weight, BP, serum lipids, BGLs, ECG (for QT interval prolongation), smoking status. For more information refer to: NPS Antipsychotic Monitoring Tool</p>
Clinical Guidelines and Policies	<p>HDWA Policies: WA Mental Health Charts</p> <p>WNHS Policies: KEMH Mental Health Emergency File</p> <p>KEMH Clinical Guidelines: Palliative Care Mental Health Emergency, Management of Pre-operative Medication Management</p> <p>KEMH Pharmaceutical & Medicines Management Guidelines: KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration</p>
References	<p>Australian Medicines Handbook. Haloperidol. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Apr 17]. Available from: https://amhonline.amh.net.au/</p>

	<p>Therapeutic Guidelines. Bowel Obstruction in Palliative Care. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2020 [cited 2020 Apr 17]. Available from: https://tgldcdp.tg.org.au</p> <p>Society of Hospital Pharmacists of Australia. Adenosine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales] Health Communication Network; 2020 [cited 2020 Apr 17]. Available from: http://aidh.hcn.com.au</p>
--	--

Keywords:	Haloperidol, Palliative Care, end of life care, Serenace, Haldol, agitation		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	January 2013	Version:	4.0
Last reviewed:	May 2020	Next review date:	May 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety, 8  Acute Deterioration		

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020